When Two Temporary Disruptions Get Priced as Permanent at Chemed

Chemed raised 2026 adjusted EPS guidance to $24.00-$24.75 from $23.25-$24.25, while VITAS Medicare Cap expense fell to $2.4 million in Q1 2026 and full-year VITAS growth guidance was lifted. Offsetting that, Roto-Rooter margin guidance was cut to 21.5%-22.5% from 22.5%-23.0% due to structurally higher digital lead costs and restoration write-offs. The stock trades about 17.4x forward earnings with a roughly 0.6% dividend yield and continued buybacks, supporting a constructive but mixed setup.

Analysis

The market is still pricing CHE as if Roto-Rooter’s margin normalization is the base case and VITAS’s cap issue was an earnings-quality scar. I think the more important signal is that management is using short-stay mix management as a tactical bridge while the underlying hospice census continues to compound; once that mix normalizes, operating leverage should reappear faster than consensus models allow because the fixed clinical overhead is already in place. The bigger second-order effect is that the buyback accelerates exactly when the stock is depressed, so each quarter of stable guidance mechanically increases per-share EPS even if consolidated operating profit only inches higher.

The key contrarian point is that the market may be over-penalizing the structural shift in customer acquisition for Roto-Rooter while underappreciating how much of CHE’s valuation support now comes from capital allocation, not multiple expansion. A 400 bps margin reset sounds severe, but on a no-net-debt balance sheet with 5.7% earnings yield and 3-4% annual share shrink, the business only needs modest top-line growth to keep double-digit owner returns intact. In other words, the bear case on the plumbing unit can be true and the stock can still be too cheap if VITAS continues to accelerate and buybacks remain aggressive.

The main risk is that the hospice cap arithmetic is not truly “fixed,” just deferred: any recurrence in Florida or spillover in California would hit as a surprise and force another mix shift, which would compress margins right when investors expect recovery. On the demand side, Roto-Rooter’s paid-lead inflation looks sticky over a 6-12 month horizon, so the near-term catalyst is not a margin rebound but evidence that the guided 21.5-22.5% range is the new floor. That makes the next quarterly print the decisive inflection point: if VITAS ADC holds and Roto-Rooter margins do not deteriorate further, the stock likely rerates toward a mid-to-high teens multiple band rather than the five-year average.

Key Decisions for Investors

• Long CHE on any post-print weakness into the next 1-2 quarters; the risk/reward favors owning the buyback at ~17x forward EPS versus historical ~24x if VITAS guidance holds.
• For hedged exposure, pair long CHE vs short GOOGL over 3-6 months: CHE is benefiting from a structural internal capital return engine, while GOOGL remains a pressure point for Roto-Rooter’s customer acquisition costs and is a proxy for the ad-tech inflation the article highlights.
• Buy CHE Jan/Apr call spreads on dips rather than outright stock if you want convexity around the next earnings release; upside is rerating plus buyback accretion, while downside is capped by cash generation and no leverage.
• Avoid shorting CHE solely on the Roto-Rooter margin reset unless you have a catalyst for a second cut to guidance; the stock already embeds a lot of the 400 bps compression, and the balance sheet limits fundamental downside.
• If the stock rallies back toward the low-$450s before the next update, consider trimming and waiting for the next quarterly read on hospice cap accruals—this is a data-dependent story, not a momentum trade.